Abstract
Purpose: To summarise the evidence for deprescribing alpha-blockers and centrally acting antihypertensives in older people at risk of falls and to assist clinicians in deciding how to safely de-prescribe these agents. Findings: Alpha-blockers and centrally acting antihypertensives are no longer recommended for the treatment of hypertension unless all other agents are contraindicated or not tolerated. Multiple tools identify these agents as potentially inappropriate and recommend deprescribing. A number of protocols have been developed to safely guide deprescribing. Message: Safer antihypertensives are available that are associated with less adverse effects. Decision aids such as STOPPFalls can assist de-prescribing.
| Original language | English |
|---|---|
| Pages (from-to) | 675-682 |
| Number of pages | 8 |
| Journal | European Geriatric Medicine |
| Volume | 14 |
| Issue number | 4 |
| Early online date | 12 Jul 2023 |
| DOIs | |
| Publication status | Published - 31 Aug 2023 |
Bibliographical note
Funding: No funding was received for conducting this study.UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Deprescribing
- Falls
- Geriatric
- Hypertension
ASJC Scopus subject areas
- Gerontology
- Geriatrics and Gerontology
Fingerprint
Dive into the research topics of 'Centrally acting antihypertensives and alpha-blockers in people at risk of falls: therapeutic dilemmas—a clinical review'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS